2-tert.-Butyl-1,2-dihydropyridin | 42540-76-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-tert.-Butyl-1,2-dihydropyridin
• 英文别名: 2-Tert-butyl-1,2-dihydropyridine
• CAS: 42540-76-1
• 化学式: C₉H₁₅N
• 分子量: 137.225
• InChiKey: UNEVSQFKWBNATR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-tert.-Butyl-1,2-dihydropyridin 、 4-乙酰氨基苯磺酰叠氮 以100%的产率得到
  参考文献：
  名称：

  ONDRUS T. A.; KNAUS E. E.; GIAM C. S., CAN. J. CHEM., 1979, 57 NO 18, 2342-2349

  摘要：

  DOI：
• 作为产物：
  描述：

  1-(benzylsulfanyl)-N,N-dimethylmethanamine 、 Sodium sulfate-III 生成 2-tert.-Butyl-1,2-dihydropyridin
  参考文献：
  名称：

  ONDRUS T. A.; KNAUS E. E.; GIAM C. S., CAN. J. CHEM., 1979, 57 NO 18, 2342-2349

  摘要：

  DOI：

文献信息

• Substituted imidazoles as bombesin receptor subtype-3 modulators
  申请人：Dobbelaar Peter H.

  公开号：US20100204236A1

  公开（公告）日：2010-08-12

  Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.

  某些新型取代咪唑是人类炸弹肽受体的配体，特别是人类炸弹肽受体亚型-3（BRS-3）的选择性配体。因此，它们可用于治疗、控制或预防对BRS-3调节敏感的疾病和障碍，例如肥胖症和糖尿病。
• Compositions and methods for treating cancer
  申请人：The Regents of the University of California

  公开号：US10023588B2

  公开（公告）日：2018-07-17

  K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.

  K-Ras 是人类癌症中最常见的突变癌基因。本文公开了调节 K-Ras 和治疗癌症的组合物和方法。
• NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS
  申请人：Inflazome Limited

  公开号：US20200291003A1

  公开（公告）日：2020-09-17

  The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R 1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R 1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R 1 may optionally be substituted; and R 2 is a cyclic group substituted at the α-position, wherein R 2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
• US8183275B2
  申请人：——

  公开号：US8183275B2

  公开（公告）日：2012-05-22